UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2024 P 1251-7
Program Prior Authorization/Notification
Medication Jynarque® (tolvaptan)
P&T Approval Date 8/2018, 8/2019, 8/2020, 8/2021, 8/2022, 8/2023, 8/2024
Effective Date 11/1/2024
1. Background:
Jynarque is a selective vasopressin V2-receptor antagonist indicated to slow
kidney function decline in adults at risk of rapidly progressing autosomal dominant
polycystic kidney disease (ADPKD).
2. Coverage Criteriaa:
A. Autosomal Dominant Polycystic Kidney Disease
1. Initial Authorization
a. Jynarque will be approved based on of the following criterion:
(1) Diagnosis of autosomal dominant polycystic kidney disease (ADPKD)
Authorization will be issued for 12 months.
2. Reauthorization
a. Jynarque will be approved based on the following criterion:
(1) Documentation of positive clinical response to Jynarque therapy
Authorization will be issued for 12 months.
a State mandates may apply. Any federal regulatory requirements and the member specific
benefit plan coverage may also impact coverage criteria. Other policies and utilization
management programs may apply.
3. Additional Clinical Rules:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-
authorization based solely on previous claim/medication history, diagnosis codes (ICD-10)
and/or claim logic. Use of automated approval and re-approval processes varies by program
and/or therapeutic class.
• Supply limits may be in place.
© 2024 UnitedHealthcare Services, Inc.
1
4. References:
1. Jynarque [package insert]. Rockville MD: Otsuka America Pharmaceutical, Inc.; October
2020.
Program Prior Authorization/Notification – Jynarque (tolvaptan)
Change Control
8/2018 New program.
8/2019 Annual review with no changes to coverage criteria.
8/2020 Annual review with no changes to coverage criteria.
8/2021 Annual review with no changes to coverage criteria. Updated
reference.
8/2022 Annual review with no changes to coverage criteria. Added state
mandate footnote.
8/2023 Annual review with no changes to coverage criteria.
8/2024 Annual review with no changes to coverage criteria.
© 2024 UnitedHealthcare Services, Inc.
2